State Street’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.4M | Buy |
816,242
+35,340
| +5% | +$709K | ﹤0.01% | 2299 |
|
|
2025
Q1 | $15.4M | Sell |
780,902
-20,930
| -3% | -$412K | ﹤0.01% | 2276 |
|
|
2024
Q4 | $18M | Buy |
801,832
+55,888
| +7% | +$1.26M | ﹤0.01% | 2280 |
|
|
2024
Q3 | $19.1M | Buy |
745,944
+21,018
| +3% | +$537K | ﹤0.01% | 2236 |
|
|
2024
Q2 | $16.9M | Buy |
724,926
+233,078
| +47% | +$5.45M | ﹤0.01% | 2251 |
|
|
2024
Q1 | $8.65M | Buy |
491,848
+7,333
| +2% | +$129K | ﹤0.01% | 2668 |
|
|
2023
Q4 | $6.71M | Buy |
484,515
+13,663
| +3% | +$189K | ﹤0.01% | 2798 |
|
|
2023
Q3 | $6.43M | Buy |
470,852
+4,601
| +1% | +$62.9K | ﹤0.01% | 2811 |
|
|
2023
Q2 | $9.52M | Buy |
466,251
+456,827
| +4,847% | +$9.32M | ﹤0.01% | 2673 |
|
|
2023
Q1 | $206K | Sell |
9,424
-1
| -0% | -$22 | ﹤0.01% | 4068 |
|
|
2022
Q4 | $154K | Buy |
9,425
+4,125
| +78% | +$67.5K | ﹤0.01% | 4216 |
|
|
2022
Q3 | $48K | Hold |
5,300
| – | – | ﹤0.01% | 4665 |
|
|
2022
Q2 | $26K | Hold |
5,300
| – | – | ﹤0.01% | 4838 |
|
|
2022
Q1 | $40K | Hold |
5,300
| – | – | ﹤0.01% | 4833 |
|
|
2021
Q4 | $48K | Hold |
5,300
| – | – | ﹤0.01% | 4707 |
|
|
2021
Q3 | $86K | Hold |
5,300
| – | – | ﹤0.01% | 4577 |
|
|
2021
Q2 | $167K | Sell |
5,300
-22,346
| -81% | -$704K | ﹤0.01% | 4253 |
|
|
2021
Q1 | $933K | Buy |
27,646
+1,320
| +5% | +$44.5K | ﹤0.01% | 3636 |
|
|
2020
Q4 | $2.32M | Buy |
26,326
+10,323
| +65% | +$911K | ﹤0.01% | 3304 |
|
|
2020
Q3 | $1.3M | Buy |
16,003
+1,927
| +14% | +$157K | ﹤0.01% | 3358 |
|
|
2020
Q2 | $1.56M | Buy |
+14,076
| New | +$1.56M | ﹤0.01% | 3280 |
|